Germany’s Fresenius (ETR: FRE) - via its operating company Fresenius Kabi - has announced the immediate US availability of Tyenne (tocilizumab-aazg), a biosimilar of Roche’s (ROG: SIX) Actemra (tocilizumab).
Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.
Reference drug Actemra earned more than 1.2 billion Swiss francs ($1.39 billion) in sales in the USA in 2023, and 2.6 billion francs globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze